This is the classic website, which will be retired eventually. Please visit the modernized ClinicalTrials.gov instead.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04450069
Recruitment Status : Active, not recruiting
First Posted : June 29, 2020
Last Update Posted : January 24, 2024
Sponsor:
Information provided by (Responsible Party):
Calibr, a division of Scripps Research

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
CLBR001 + SWI019 is an combination investigational immunotherapy being evaluated as a potential treatment for patients diagnosed with B cell malignancies who are refractory or unresponsive to salvage therapy or who cannot be considered for or have progressed after autologous hematopoietic cell transplantation. This first-in-human study will assess the safety and tolerability of CLBR001 + SWI019 and is designed to determine the maximum tolerated dose (MTD) or optimal SWI019 dose (OSD). Patients will be administered a single infusion of CLBR001 cells followed by cycles of SWI019. The study will also assess the pharmacokinetics and pharmacodynamics of CLBR001 + SWI019.

Condition or disease Intervention/treatment Phase
Relapsed/Refractory B-cell Lymphomas Diffuse Large B Cell Lymphoma (DLBCL) Follicular Lymphoma (FL) Chronic Lymphocytic Leukemia (CLL) Marginal Zone Lymphoma (MZL) Mantle Cell Lymphoma Small Lymphocytic Lymphoma (SLL) Primary Mediastinal Large B Cell Lymphoma Transformed Follicular Lymphoma Waldenstrom Macroglobulinemia Lymphoplasmacytic Lymphoma Burkitt Lymphoma Combination Product: CLBR001 and SWI019 Phase 1

Detailed Description:
CLBR001 + SWI019 is a two-component therapy comprising an autologous chimeric antigen receptor T (CAR-T) cell product (CLBR001, the switchable CAR-T cell (sCAR-T)) and an anti-CD19 (cluster of differentiation antigen 19) antibody (SWI019, the switch, a biologic). In combination, SWI019 acts as an adapter molecule that controls the activity of the CLBR001 CAR-T cell product.
Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 18 participants
Allocation: N/A
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1, Open-label, Dose Escalating Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the Combination of CLBR001 and SWI019 in Patients With Relapsed/Refractory B-cell Malignancies
Actual Study Start Date : August 14, 2020
Estimated Primary Completion Date : April 2024
Estimated Study Completion Date : June 2024

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Dose Escalation
CLBR001 + SWI019 is administered via infusion with ascending dose levels to determine the maximum tolerated dose (MTD) or optimal SWI019 dose (OSD)
 Combination Product: CLBR001 and SWI019
Investigational immunotherapy for B cell malignancies


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Frequency, relatedness, severity and duration of treatment emergent and treatment related adverse events [ Time Frame: 35 days ]
    To determine the frequency, relatedness, severity and duration of treatment emergent and treatment related adverse events

  2. Number of first cycle dose limiting toxicities (DLT) as assessed by Common Terminology Criteria for Adverse Events (CTCAE) [ Time Frame: up to 1 year ]
    Based on the number of first cycle dose limiting toxicities (DLT) as assessed by CTCAE to determine maximum tolerated dose (MTD)


Secondary Outcome Measures :
  1. Maximum drug concentration (Cmax) of SWI019 [ Time Frame: up to Day 35 ]
    To determine the maximum concentration of SWI019 in a patient's peripheral blood

  2. Area under the curve (AUC) of SWI019 [ Time Frame: up to Day 35 ]
    To quantify the cumulative amount of SWI019 in a patient's peripheral blood over time

  3. Time to reach Cmax (Tmax) of SWI019 [ Time Frame: up to Day 35 ]
    To identify the time point when the concentration of SWI019 reaches maximum in a patient's peripheral blood

  4. Clearance (CL) of SWI019 [ Time Frame: up to Day 35 ]
    To determine the clearance factor of SWI019 in a patient's peripheral blood

  5. Apparent elimination half-life (t1/2) of SWI019 [ Time Frame: up to Day 35 ]
    To identify the time point when the concentration of SWI019 reaches half of maximum in a patient's peripheral blood

  6. Quantification of CLBR001 cells in peripheral blood [ Time Frame: up to 1 year ]
    To quantify CLBR001 in a patient's peripheral blood at different time points

  7. Phenotype of CLBR001 in peripheral blood and/or tumor/bone marrow biopsies [ Time Frame: up to 1 year ]
    To evaluate the phenotype of CLBR001 in a patient's peripheral blood at different time points by flow cytometry

  8. Immunogenic response to CLBR001 [ Time Frame: up to 1 year ]
    To evaluate the anti-drug antibodies in response to CLBR001 administration in a patient's peripheral blood

  9. Immunogenic response to SWI019 [ Time Frame: up to 1 year ]
    To evaluate the anti-drug antibodies in response to SWI019 administration in a patient's peripheral blood

  10. Serum cytokine concentrations [ Time Frame: up to 1 year ]
    To measure the cytokine levels (e.g. TNFa, IL-6, IL-1, IL-2, etc.) in a patient's peripheral blood at different time points

  11. Overall (best) objective response by the Response Evaluation Criteria in Lymphoma (RECIL) and Lugano criteria [ Time Frame: up to 1 year ]
    To determine the overall (best) objective anti-cancer response by RECIL and Lugano criteria

  12. Duration of response (DOR) [ Time Frame: up to 1 year ]
    To evaluate the duration of anti-cancer response after CLBR001 and SWI019 administration

  13. Progression free survival (PFS) [ Time Frame: up to 1 year ]
    To evaluate the duration of patient's progression-free survival

  14. Overall survival (OS) [ Time Frame: up to 1 year ]
    To evaluate the overall duration of patient's survival


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with relapsed / refractory previously treated B cell malignancies (according to the World Health Organization classification; 2017)
  • Patients must have received adequate prior therapy including at least two lines of prior therapies including anthracycline or bendamustine-containing chemotherapy, anti-CD20 (cluster of differentiation antigen 20) therapies and/or Brutton's tyrosine kinase (BTK) inhibitors
  • Patients treated with prior CD19 targeted molecules (e.g., Blincyto) must have confirmed CD19+ disease
  • Patients must be ineligible for allogeneic stem cell transplant (SCT)
  • Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 or 1
  • Estimated life expectancy of ≥ 12 weeks from the first day of SWI019 dose administered
  • Willing to undergo pre- and post-treatment core needle biopsy
  • Adequate hematological, renal, pulmonary, cardiac, and liver function
  • Resolved adverse events of any prior therapy to either baseline or CTCAE Grade ≤1
  • Women of childbearing potential, a negative pregnancy test and must agree to practice effective birth control
  • Men sexually active with female partners of child bearing potential must agree to practice effective contraception
  • Willing and able to comply with scheduled visits, treatment plan, laboratory tests and other procedures

Exclusion Criteria:

  • Patients diagnosed with certain disease histologies including pediatric lymphomas/leukemias, monoclonal gammopathy of undetermined significance (MGUS), T-cell histiocyte large B cell lymphoma
  • Pregnant or lactating women
  • Active bacterial, viral, and fungal infections
  • History of allogeneic stem cell transplantation
  • Treatment with any prior lentiviral or retroviral based CAR-T
  • Patients receiving live (attenuated) vaccines within 4 weeks of screening visit or need for live vaccine on study
  • Patients with known active central nervous system (CNS) disease. Patients with prior CNS disease that has been effectively treated may be eligible
  • History of Class III or IV New York Heart Association (NYHA) heart failure, myocardial infarction, unstable angina or other significant cardiac disease within 6 months of screening
  • Involvement of cardiac tissue by lymphoma
  • Uncontrolled autoimmune hemolytic anemia or idiopathic thrombocytopenic purpura (ITP)
  • HIV-1 and HIV-2 antibody positive patients
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04450069


Locations
Layout table for location information
United States, California
City of Hope National Medical Center
Duarte, California, United States, 91010
University of California at San Diego
San Diego, California, United States, 92093
United States, Illinois
University of Chicago
Chicago, Illinois, United States, 60637
United States, Minnesota
Masonic Cancer Center, University of Minnesota
Minneapolis, Minnesota, United States, 55455
United States, New York
Weill Cornell Medical College - New York Presbyterian Hospital
New York, New York, United States, 10065
United States, North Carolina
Wake Forest Baptist Health
Winston-Salem, North Carolina, United States, 27157
United States, Tennessee
Sarah Cannon Research Institute - Tennessee Oncology
Nashville, Tennessee, United States, 37203
United States, Texas
Sarah Cannon Research Institute - Texas Transplant Institute
San Antonio, Texas, United States, 78229
Sponsors and Collaborators
Calibr, a division of Scripps Research
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Publications:

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Layout table for additonal information
Responsible Party: Calibr, a division of Scripps Research
ClinicalTrials.gov Identifier: NCT04450069    
Other Study ID Numbers: CBR-sCAR19-3001
First Posted: June 29, 2020    Key Record Dates
Last Update Posted: January 24, 2024
Last Verified: January 2024
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Calibr, a division of Scripps Research:
CAR-T Cell Therapy
Switchable CAR-T Cell
Autologous Cell Therapy
CD19 Positive Disease
 CD19 CAR-T Cell
Blood Cancer
Hematological malignancy
Neoplasms
Additional relevant MeSH terms:
Layout table for MeSH terms
Burkitt Lymphoma
Lymphoma
Neoplasms
Lymphoma, Follicular
Lymphoma, B-Cell
Leukemia, Lymphocytic, Chronic, B-Cell
Lymphoma, Mantle-Cell
Lymphoma, Large B-Cell, Diffuse
Waldenstrom Macroglobulinemia
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Lymphoma, Non-Hodgkin
 Leukemia, Lymphoid
Leukemia
Hematologic Diseases
Leukemia, B-Cell
Chronic Disease
Disease Attributes
Pathologic Processes
Epstein-Barr Virus Infections
Herpesviridae Infections
DNA Virus Infections
Virus Diseases
Infections
Tumor Virus Infections
Neoplasms, Plasma Cell
Hemostatic Disorders